Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20548252 | 0.92 | CHRM4 (0.36) | NTRK1CHRM4XIAPCNR1P2RX7 | |
| SCHEMBL30373743 | 0.92 | CHRM4 (0.36) | NTRK1CHRM4XIAPCNR1P2RX7 | |
| SCHEMBL22077544 | 0.91 | PDE4B (0.37) | NTRK1CHRM4P2RX7BRD4CREBBP | |
| SCHEMBL30373914 | 0.91 | PDE4B (0.37) | NTRK1CHRM4P2RX7BRD4CREBBP | |
| SCHEMBL30373935 | 0.90 | NTRK1 (0.36) | NTRK1CHRM4XIAPCNR1CNR2 | |
| SCHEMBL20547510 | 0.90 | NTRK1 (0.36) | NTRK1CHRM4XIAPCNR1CNR2 | |
| SCHEMBL30373929 | 0.89 | NTRK1 (0.36) | NTRK1CHRM4XIAPCNR1P2RX7 | |
| SCHEMBL22077537 | 0.89 | NTRK1 (0.36) | NTRK1CHRM4XIAPCNR1P2RX7 | |
| SCHEMBL20547556 | 0.89 | P2RX7 (0.36) | NTRK1CHRM4XIAPCNR1P2RX7 | |
| SCHEMBL30373567 | 0.89 | P2RX7 (0.36) | NTRK1CHRM4XIAPCNR1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3585791-B1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-10-16 | — | — | EP | disclosed |
| CN-110536892-B | Novel bicyclic pyrazole derivatives | 拜耳动物保健有限责任公司 | 2023-05-12 | — | — | CN | disclosed |
| US-11130768-B2 | Bicyclic pyrazole derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| US-11130768-B2 | Bicyclic pyrazole derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| US-20200190111-A1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20200190111-A1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
| WO-2018197401-A1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190111-A1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | CYP1B1, QPCT, CYP4B1 | NTRK1 4860/4885CHRM4 1442/4885XIAP 4019/4885 |
| US-11130768-B2 | Bicyclic pyrazole derivatives | CYP1B1, CYP3A43, CYP3A5 | NTRK1 4872/4885CHRM4 1513/4885XIAP 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.